Results 11 to 20 of about 16,675 (216)

Disulfiram Reduces Atherosclerosis and Enhances Efferocytosis, Autophagy, and Atheroprotective Gut Microbiota in Hyperlipidemic Mice

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Pyroptosis executor GsdmD (gasdermin D) promotes atherosclerosis in mice and humans. Disulfiram was recently shown to potently inhibit GsdmD, but the in vivo efficacy and mechanism of disulfiram's antiatherosclerotic activity is yet to be ...
C. Alicia Traughber, Kara Timinski, Ashutosh Prince, Nilam Bhandari, Kalash Neupane, Mariam R. Khan, Esther Opoku, Emmanuel Opoku, Gregory Brubaker, Junchul Shin, Junyoung Hong, Babunageswararao Kanuri, Elif G. Ertugral, Prabhakara R. Nagareddy, Chandrasekhar R. Kothapalli, Olga Cherepanova, Jonathan D. Smith, Kailash Gulshan   +17 more
doaj   +2 more sources

Disulfiram and cancer immunotherapy: Advanced nano-delivery systems and potential therapeutic strategies

International Journal of Pharmaceutics: X
The initial focus of the clinical application of disulfiram was its efficacy in treating alcoholism. However, recent research has revealed its potential as an anti-tumor agent and even as an enhancer of cancer immunotherapy.
Di Huang, Yinsha Yao, Yifei Lou, Longfa Kou, Qing Yao, Ruijie Chen   +5 more
doaj   +2 more sources

Disulfiram ameliorates ischemia/reperfusion-induced acute kidney injury by suppressing the caspase-11-GSDMD pathway

Renal Failure, 2022
Acute kidney injury (AKI) is a serious condition with high mortality. The most common cause is kidney ischemia/reperfusion (IR) injury, which is thought to be closely related to pyroptosis.
Qiaoting Cai, Zhaoxing Sun, Sujuan Xu, Xiaoyan Jiao, Shulan Guo, Yingxiang Li, Huan Wu, Xiaofang Yu   +7 more
doaj   +2 more sources

Repurposing disulfiram, an alcohol-abuse drug, in neuroblastoma causes KAT2A downregulation and in vivo activity with a water/oil emulsion

Scientific Reports, 2023
Neuroblastoma, the most common type of pediatric extracranial solid tumor, causes 10% of childhood cancer deaths. Despite intensive multimodal treatment, the outcomes of high-risk neuroblastoma remain poor.
Annie Beaudry, Simon Jacques-Ricard, Anaïs Darracq, Nicolas Sgarioto, Araceli Garcia, Teresita Rode García, William Lemieux, Kathie Béland, Elie Haddad, Paulo Cordeiro, Michel Duval, Serge McGraw, Chantal Richer, Maxime Caron, François Marois, Pascal St-Onge, Daniel Sinnett, Xavier Banquy, Noël J.-M. Raynal   +18 more
doaj   +2 more sources

Application of Disulfiram and its Metabolites in Treatment of Inflammatory Disorders

Frontiers in Pharmacology, 2022
Disulfiram has been used clinically for decades as an anti-alcoholic drug. Recently, several studies have demonstrated the anti-inflammatory effects of disulfiram and its metabolism, which can alleviate the progression of inflammation in vivo and in ...
Wenyi Guo, Shihong Chen, Chengqing Li, Jianwei Xu, Lei Wang   +4 more
doaj   +2 more sources

Disulfiram alleviates acute lung injury and related intestinal mucosal barrier impairment by targeting GSDMD-dependent pyroptosis

Journal of Inflammation, 2022
Background Pyroptosis was implicated in acute lung injury (ALI). Disulfiram is reported as an effective pyroptosis inhibitor by inhibiting gasdermin D(GSDMD).
Jiping Zhao, Hong Wang, Jintao zhang, Fuwei Ou, Junfei Wang, Tian Liu, Jinxiang Wu   +6 more
doaj   +2 more sources

Disulfiram attenuates hypoxia-induced pulmonary hypertension by inhibiting GSDMD cleavage and pyroptosis in HPASMCs

Respiratory Research, 2022
Background Pulmonary hypertension (PH) is characterized by progressive pulmonary arterial remodelling, associated with different severities of inflammation and altered immune processes.
Shunlian Hu, Lu Wang, Yahan Xu, Fajiu Li, Tao Wang   +4 more
doaj   +2 more sources

Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis

Redox Biology, 2021
Hepatocellular carcinoma (HCC) is one of the paramount causes of cancer-related death worldwide. Despite recent advances have been made in clinical treatments of HCC, the general prognosis of patients remains poor.
Xueying Ren, Yanchun Li, Yi Zhou, Wanye Hu, Chen Yang, Qiangan Jing, Chaoting Zhou, Xu Wang, Jiayu Hu, Luyang Wang, Jing Yang, Hairui Wang, Haifeng C. Xu, Huanjuan Li, Xiangmin Tong, Ying Wang, Jing Du   +16 more
semanticscholar   +1 more source

Disulfiram blocks inflammatory TLR4 signaling by targeting MD-2

Proceedings of the National Academy of Sciences of the United States of America, 2023
Significance In response to pathogen/damage-associated molecular patterns, Toll-like receptor 4 (TLR4) initiates a host innate immune inflammatory response to control infection, tissue repair, and regeneration, while aberrant activation of TLR4 causes ...
Yang Bai, Rui Min, Pengcheng Chen, S. Mei, Fan Deng, Zengzhang Zheng, Cong Jiang, R. Miao, Zeyu Wu, Peng Zhang, Youdong Pan, J. Lieberman, Xing Liu   +12 more
semanticscholar   +1 more source

FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation

Nature Immunology, 2020
Cytosolic sensing of pathogens and damage by myeloid and barrier epithelial cells assembles large complexes called inflammasomes, which activate inflammatory caspases to process cytokines (IL-1β) and gasdermin D (GSDMD).
J. Hu, Xing Liu, S. Xia, Zhibin Zhang, Ying Zhang, Jingxia Zhao, J. Ruan, Xuemei Luo, Xiwen Lou, Yang Bai, Junhong Wang, L. R. Hollingsworth, V. Magupalli, Li Zhao, Hongbo R. Luo, Justin Kim, J. Lieberman, Hao Wu   +17 more
semanticscholar   +1 more source